InterVenn’s data show that glycoproteomic based assays are uniquely informative and successful in predicting the clinical course of a disease, in stratifying patient populations, and in selecting efficient and safe therapies. Whether you are at the pre-clinical, clinical, or commercial stages of drug development, we can optimize your chances of success by identifying the right patient cohorts and development strategies for your new therapies.
You have molecules/candidates and would like to enrich your patient recruitment by selecting predicted likely responders to enhance the chances of a successful trial.
You have conducted a trial that may benefit from additional insight into attributes of patients who have, or have not responded to your innovative medicine.
You need to predict which patients are likely to experience adverse effects of a new molecule.
